

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

COALITION FOR AFFORDABLE DRUGS IV LLC

Petitioner

v.

PHARMACYCLICS, INC.

Patentee

---

Case IPR2015-01076

U.S. Patent No. 8,754,090

TITLE: USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK)

Issue Date: June 17, 2014

---

**PETITIONER'S UPDATED APPENDIX OF EXHIBITS**

---

<b>Exhibit</b>	<b>Description</b>	<b>Filed</b>
Ex. 1001	U.S. Patent No. 8,754,090	<input checked="" type="checkbox"/>
Ex. 1002	ClinicalTrials.gov Archive, <i>Study of the Safety and Tolerability of PIC-32765 in Patients with Recurrent B Cell Lymphoma</i> (February 23, 2009), <a href="https://clinicaltrials.gov/archive/NCT00849654/2009_02_23">https://clinicaltrials.gov/archive/NCT00849654/2009_02_23</a>	<input checked="" type="checkbox"/>
Ex. 1003	U.S. Patent App. Pub. No. 2008/0139582	<input checked="" type="checkbox"/>
Ex. 1004	Press Release, Pharamacyclics, Pharamacyclics Initiates Phase I Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-Cell Non-Hodgkin's Lymphoma (April 13, 2009)	<input checked="" type="checkbox"/>
Ex. 1005	Zhengying Pan, et al., <i>Discovery of Selective Irreversible Inhibitors for Bruton's Tyrosine Kinase</i> , 2 ChemMedChem 58 (2007)	<input checked="" type="checkbox"/>
Ex. 1006	Lee Honigberg et al., <i>Targeting Btk in Lymphoma: PCI-32765 Inhibits Tumor Growth in Mouse Lymphoma Models and a Fluorescent Analog of PCI-32675 Is an Active-Site Probe That Enables Assessment of Btk Inhibition In Vivo</i> , Blood (ASH Annual Meeting Abstracts) at 1592 (November 2007)	<input checked="" type="checkbox"/>
Ex. 1007	Christophe Le Tourneau et al., <i>Dose Escalation Methods in Phase I Cancer Clinical Trials</i> , 101 J. Nat'L Cancer Inst. 708 (2009)	<input checked="" type="checkbox"/>
Ex. 1008	Jonathan McConathy, Ph.D., & Michael J. Owens, Ph.D., <i>Stereochemistry in Drug Action</i> , 5 Primary Care Companion J Clinical Psychiatry 70 (2003)	<input checked="" type="checkbox"/>
Ex. 1009	Stefano A. Pileri & Brunangelo Falini, <i>Mantle Cell Lymphoma</i> , 94 Haematologica 1488 (2009)	<input checked="" type="checkbox"/>
Ex. 1010	Agency For Toxic Substances and Disease Registry, Public Health Assessment Guidance Manual, (2005)	<input checked="" type="checkbox"/>
Ex. 1011	MacPartlin et al., <i>Bruton's tyrosine kinase is not essential for Bcr-Abl-mediated transformation of lymphoid or myeloid cells</i> , 22 Leukemia 1354 (2008)	<input checked="" type="checkbox"/>
Ex. 1012	National Center for Biotechnology Information, PubChem Compound Database, CID=16126651, available at <a href="http://pubchem.ncbi.nlm.nih.gov/compound/16126651">http://pubchem.ncbi.nlm.nih.gov/compound/16126651</a>	<input checked="" type="checkbox"/>
Ex. 1013	Elaine S. Jaffe, <i>The 2008 WHO classification of lymphomas: implications for clinical practice and</i>	<input checked="" type="checkbox"/>

	<i>translational research</i> , Hematology (2009)	
Ex. 1014	Original Claims, December 29, 2011, U.S. Patent App. No. 13/340,522	<input checked="" type="checkbox"/>
Ex. 1015	Examiner Initiated Interview Summary, December 23, 2012, U.S. Patent App. No. 13/340,522	<input checked="" type="checkbox"/>
Ex. 1016	Requirement for Restriction/Election, January 3, 2013, U.S. Patent App. No. 13/340,522	<input checked="" type="checkbox"/>
Ex. 1017	Preliminary Amendment and Response to Restriction Requirement, February 4, 2013, U.S. Patent App. No. 13/340,522	<input checked="" type="checkbox"/>
Ex. 1018	Final Office Action, November 1, 2013, U.S. Patent App. No. 13/340,522	<input checked="" type="checkbox"/>
Ex. 1019	Response to Final Office Action, December. 17, 2013, U.S. Patent App. No. 13/340,522	<input checked="" type="checkbox"/>
Ex. 1020	Notice of Allowance, January 27, 2014, U.S. Patent App. No. 13/340,522	<input checked="" type="checkbox"/>
Ex. 1021	Declaration by Djordje Atanackovic, M.D., Regarding U.S. Patent No. 8,754,090 Under 37 C.F.R. § 42.63(a)	<input checked="" type="checkbox"/>
Ex. 1022	Curriculum Vitae of Djordje Atanackovic, M.D.	<input checked="" type="checkbox"/>
Ex. 1023	R. Eric Davis, et al., <i>Chronic Active B-Cell-Receptor Signalling in Diffuse Large B-Cell Lymphoma</i> , Nature, Vol. 463, Letters, pp. 88-92 (January 7, 2010)	<input checked="" type="checkbox"/>
Ex. 1024	Declaration of Brent Routman in Support of Petitioner's Motion for Admission <i>Pro Hac Vice</i>	<input checked="" type="checkbox"/>
Ex. 1025	Declaration of Shane A. Brunner in Support of Petitioner's Motion for Admission <i>Pro Hac Vice</i>	<input checked="" type="checkbox"/>